These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
315 related articles for article (PubMed ID: 26033112)
1. Predictive factors for oocyte retrieval failure in controlled ovarian hyperstimulation protocols: a retrospective observational cohort study. Hasegawa A; Takahashi T; Igarashi H; Amita M; Matsukawa J; Nagase S Reprod Biol Endocrinol; 2015 Jun; 13():53. PubMed ID: 26033112 [TBL] [Abstract][Full Text] [Related]
2. A simplified universal approach to COH protocol for IVF: ultrashort flare GnRH-agonist/GnRH-antagonist protocol with tailored mode and timing of final follicular maturation. Orvieto R J Ovarian Res; 2015 Nov; 8():69. PubMed ID: 26536862 [TBL] [Abstract][Full Text] [Related]
3. Assessing the adequacy of gonadotropin-releasing hormone agonist leuprolide to trigger oocyte maturation and management of inadequate response. Chang FE; Beall SA; Cox JM; Richter KS; DeCherney AH; Levy MJ Fertil Steril; 2016 Oct; 106(5):1093-1100.e3. PubMed ID: 27341988 [TBL] [Abstract][Full Text] [Related]
4. Dual trigger for final oocyte maturation improves the oocyte retrieval rate of suboptimal responders to gonadotropin-releasing hormone agonist. Lu X; Hong Q; Sun L; Chen Q; Fu Y; Ai A; Lyu Q; Kuang Y Fertil Steril; 2016 Nov; 106(6):1356-1362. PubMed ID: 27490046 [TBL] [Abstract][Full Text] [Related]
6. Predicting suboptimal oocyte yield following GnRH agonist trigger by measuring serum LH at the start of ovarian stimulation. Popovic-Todorovic B; Santos-Ribeiro S; Drakopoulos P; De Vos M; Racca A; Mackens S; Thorrez Y; Verheyen G; Tournaye H; Quintero L; Blockeel C Hum Reprod; 2019 Oct; 34(10):2027-2035. PubMed ID: 31560740 [TBL] [Abstract][Full Text] [Related]
7. Follicular fluid anti-Müllerian hormone and inhibin B concentrations: comparison between gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist cycles. Lee JR; Kim SH; Kim SM; Jee BC; Ku SY; Suh CS; Choi YM; Kim JG; Moon SY Fertil Steril; 2008 Apr; 89(4):860-7. PubMed ID: 18249372 [TBL] [Abstract][Full Text] [Related]
8. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment. Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285 [TBL] [Abstract][Full Text] [Related]
9. Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study. Bodri D; Guillén JJ; Galindo A; Mataró D; Pujol A; Coll O Fertil Steril; 2009 Feb; 91(2):365-71. PubMed ID: 18367175 [TBL] [Abstract][Full Text] [Related]
10. Controlled ovarian hyperstimulation using multi-dose gonadotropin-releasing hormone (GnRH) antagonist results in less systemic inflammation than the GnRH-agonist long protocol. Orvieto R; Volodarsky M; Hod E; Homburg R; Rabinson J; Zohav E; Anteby EY; Meltcer S Gynecol Endocrinol; 2007; 23(8):494-6. PubMed ID: 17852411 [TBL] [Abstract][Full Text] [Related]
11. Dual trigger with combination of gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves the live-birth rate for normal responders in GnRH-antagonist cycles. Lin MH; Wu FS; Lee RK; Li SH; Lin SY; Hwu YM Fertil Steril; 2013 Nov; 100(5):1296-302. PubMed ID: 23993928 [TBL] [Abstract][Full Text] [Related]
12. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Humaidan P; Bredkjaer HE; Bungum L; Bungum M; Grøndahl ML; Westergaard L; Andersen CY Hum Reprod; 2005 May; 20(5):1213-20. PubMed ID: 15760966 [TBL] [Abstract][Full Text] [Related]
13. The usefulness of peri-trigger female reproductive hormones (delta-FRH) in predicting oocyte maturation in normal ovarian reserve patients who received He L; Xu Q; Wan F; Hao L; Qiu Y; Ran X; Lin J; Chen W PeerJ; 2024; 12():e17706. PubMed ID: 39006021 [TBL] [Abstract][Full Text] [Related]
14. Does the estradiol level on the day of human chorionic gonadotropin administration predict the clinical outcome of controlled ovarian hyperstimulation? Erzincan SG; Esmer AC; Baysal B Clin Exp Obstet Gynecol; 2014; 41(6):709-12. PubMed ID: 25551969 [TBL] [Abstract][Full Text] [Related]
15. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study. Humaidan P; Ejdrup Bredkjaer H; Westergaard LG; Yding Andersen C Fertil Steril; 2010 Feb; 93(3):847-54. PubMed ID: 19200959 [TBL] [Abstract][Full Text] [Related]
16. Co-administration of GnRH-agonist and hCG, for final oocyte maturation (double trigger), in patients with low proportion of mature oocytes. Zilberberg E; Haas J; Dar S; Kedem A; Machtinger R; Orvieto R Gynecol Endocrinol; 2015 Feb; 31(2):145-7. PubMed ID: 25385007 [TBL] [Abstract][Full Text] [Related]
17. Is the type of gonadotropin-releasing hormone suppression protocol for ovarian hyperstimulation associated with ectopic pregnancy in fresh autologous cycles for in vitro fertilization? Londra L; Moreau C; Strobino D; Bhasin A; Zhao Y Fertil Steril; 2016 Sep; 106(3):666-72. PubMed ID: 27320035 [TBL] [Abstract][Full Text] [Related]
18. Anti-Müllerian hormone for the assessment of ovarian response in GnRH-antagonist-treated oocyte donors. Polyzos NP; Stoop D; Blockeel C; Adriaensen P; Platteau P; Anckaert E; Smitz J; Devroey P Reprod Biomed Online; 2012 May; 24(5):532-9. PubMed ID: 22417669 [TBL] [Abstract][Full Text] [Related]
19. The influence of estradiol/follicle and estradiol/oocyte ratios on the outcome of controlled ovarian stimulation for in vitro fertilization. Orvieto R; Zohav E; Scharf S; Rabinson J; Meltcer S; Anteby EY; Homburg R Gynecol Endocrinol; 2007 Feb; 23(2):72-5. PubMed ID: 17454155 [TBL] [Abstract][Full Text] [Related]
20. Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization. Fauser BC; de Jong D; Olivennes F; Wramsby H; Tay C; Itskovitz-Eldor J; van Hooren HG J Clin Endocrinol Metab; 2002 Feb; 87(2):709-15. PubMed ID: 11836309 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]